Date & Location
Wednesday, November 1, 2017 12:00 PM - 5:00 PM
Rio Hotel, Las Vegas, NV
Target Audience
Oncology Navigator, Radiology/Imaging, Surgery, Urology
Overview
Stereotactic Body Radiation Therapy (SBRT) has emerged as an exciting and validated treatment option for men with localized prostate cancer. This is supported by the unique radiobiology of prostatic adenocarcinoma coupled with innovations in treatment delivery. Long-term data continues to emerge demonstrating favorable biochemical control with low normal tissue toxicity. This symposium is designed to provide physicians with an overview of the long-term data, as well as to explore the clinical questions that remain regarding optimizing the use of SBRT for cure while minimizing sidee?ects. To promote understanding of the intricacies of SBRT, an internationally renowned group of clinician scientists has been assembled to lead this discussion.
Objectives
- Describe the radiobiologic and physics-related rationale for employing stereotactic body radiation therapy for prostate cancer
- Analyze appropriate candidates for prostate SBRT as well as expected outcomes related to biochemical control and toxicity.
- Integrate holistic approaches with conventional management of localized disease.
- Discuss controversies and future directions regarding SBRT for prostate cancer, including sequencing with more conventional therapies and changes in prescribed dose to tumor and normal tissue.
Registration
There is no registration fee.
Accreditation
AMA Accreditation
NYU Winthrop Hospital designates this live activity for a maximum of
4.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit
commensurate with the extent of their participation in the activity.
Non-Physicians will receive a certificate of completion, and can seek
reciprocal credit recognition directly from their professional organization